{"id":134504,"name":"NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)","slug":"national-organization-for-rare-disorders-inc-nord","state":"DC","country":"United States of America","description":"","totalSpending":2150000,"filings":38,"yearlySpending":[{"year":2018,"income":270000},{"year":2019,"income":320000},{"year":2020,"income":360000},{"year":2021,"income":360000},{"year":2022,"income":210000},{"year":2023,"income":140000},{"year":2024,"income":240000},{"year":2025,"income":250000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"},{"code":"PHA","display":"Pharmacy"},{"code":"BUD","display":"Budget/Appropriations"},{"code":"CPT","display":"Copyright/Patent/Trademark"},{"code":"IMM","display":"Immigration"},{"code":"TAX","display":"Taxation/Internal Revenue Code"}],"firms":["NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD)"],"lobbyists":["PAUL MELMEYER","MELANIE SWICK BUZZELLI","PETER SALTONSTALL","RACHEL SHER","ROSE AVELLINO GALLAGHER","TIMOTHY BOYD","MICHELLE ADAMS","CORINNE ALBERTS","HEIDI ROSS","RICHARD WHITE","RUBY DEHKHARGHANI","KARIN HOELZER","ALLISON HERRITY","HAYLEY MASON","MASON BARRETT","SUPRAJA SOWMIYANARAYAN","VICTORIA GEMME"],"govEntities":["Centers For Medicare and Medicaid Services (CMS)","Food & Drug Administration (FDA)","Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","Natl Institutes of Health (NIH)","SENATE","Office of Management & Budget (OMB)","Bureau of Citizenship & Immigration Services (BCIS)","Homeland Security, Dept of (DHS)","Centers For Disease Control & Prevention (CDC)","Social Security Administration (SSA)","Natl Institute of Standards & Technology (NIST)"],"sampleDescriptions":["Bipartisan Health Care Stabilization Act \nMedicare Part D \nRight to Try Act; H.R.5247, S.204\nRare disease Advancement, Research, and Education Act of 2018; H.R.5115\nNational Institutes of Health Fundi","Medicare Part D \nRight to Try Act; S.204\nRare disease Advancement, Research, and Education Act of 2018; H.R.5115\nNational Institutes of Health funding\nFood and Drug Administration Appropriations \nOrph","Medicare Part D \nStep therapy in Medicare Advantage plans \nRestoring the Patient's Voice Act of 2017; H.R.2077\nRare disease Advancement, Research, and Education Act of 2018; H.R.5115\nNational Institut","Medicare Part D \nAffirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and develop","Medicare issues impacting patients with rare diseases.\nMedicare Part D."]}